MiSL identified several predictive biomarkers for MK-2206 (Fig. 4c), including PIK3CA mutation in breast cancer, which was identified because PIK3CA mutation and AKT1 deletion were mutually exclusive in pan-cancer data, AKT1 deletion resulted in lowered expression and AKT1 was overexpressed in PIK3CA-mutant breast cancer (Supplementary Fig. 5d). Here, PIK3CA is linked to breast cancer.